Erratum: Liver-Specific GH Receptor Gene-Disrupted (LiGHRKO) Mice Have Decreased Endocrine IGF-I, Increased Local IGF-I, and Altered Body Size, Body Composition, and Adipokine Profiles (Endocrinology (United States) (2014) 155:5 (1793-1805) DOI: 10.1210/en.2013-2086);Liver-Specific gh receptor gene-Disrupted (lighrko) mice have decreased endocrine igf-I, increased local igf-I, and altered body size, body composition, and adipokine profiles

Endocrinology

Volumn 155, Issue 5, 2014, Pages 1793-1805

  List, Edward O ^a,b   Berryman, Darlene E ^a,c   Funk, Kevin ^d   Jara, Adam ^a,c   Kelder, Bruce ^a   Wang, Feiya ^a   Stout, Michael B ^e   Zhi, Xu ^f   Sun, Liou ^g   White, Thomas A ^e   LeBrasseur, Nathan K ^e   Pirtskhalava, Tamara ^e   Tchkonia, Tamara ^e   Jensen, Elizabeth A ^a   Zhang, Wenjuan ^a   Masternak, Michal M ^f   Kirkland, James L ^d   Miller, Richard A ^g   Bartke, Andrzej ^d   Kopchick, John J ^a,c  

^a OHIO UNIVERSITY   (United States)

^b School of Applied Health Sciences and Wellness   (United States)

^c OHIO UNIVERSITY   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C PEPTIDE; COMPLEMENT FACTOR D; GLUCOSE; GROWTH HORMONE RECEPTOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 6; LEPTIN; LIVER SPECIFIC GROWTH HORMONE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; RESISTIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 7; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY SIZE; BODY WEIGHT; CONTROLLED STUDY; ENDURANCE; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; GENE DISRUPTION; GENE EXPRESSION; GENE INACTIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GRIP STRENGTH; INSULIN BLOOD LEVEL; LIVER; LIVER HISTOLOGY; LOXP SITE; MALE; MOUSE; NONHUMAN; OBESITY; ORGAN SIZE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TREADMILL; WESTERN BLOTTING;

ADIPOKINES; ADIPOSE TISSUE, WHITE; ADIPOSITY; AGING; ANIMALS; BODY COMPOSITION; BODY SIZE; ENDOCRINE GLANDS; FEMALE; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; RECEPTORS, SOMATOTROPIN; RNA, MESSENGER; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION;

EID: 84899431801     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/endocr/bqae065     Document Type: Erratum

References (72)

1. Zhou Y, Xu BC, Maheshwari HG, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA. 1997;94:13215-13220.
2. List EO, Sackmann-Sala L, Berryman DE, et al. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse. Endocr Rev. 2011;32:356-386.
3. Berryman DE, List EO, Palmer AJ, et al. Two-year body composition analyses of long-livedGHRnull mice. J GerontolABiol SciMed Sci. 2010;65:31-40.
4. Berryman DE, List EO, Sackmann-Sala L, Lubbers E, Munn R, Kopchick JJ. Growth hormone and adipose tissue: beyond the adipocyte. Growth Horm IGF Res. 2011;21:113-123.
5. Dominici FP, Arostegui Diaz G, Bartke A, Kopchick JJ, Turyn D. Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice. J Endocrinol. 2000;166: 579-590.
6. Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A, Kopchick JJ. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology. 2003;144:3799-3810.
7. Bonkowski MS, Pamenter RW, Rocha JS, Masternak MM, Panici JA, Bartke A. Long-lived growth hormone receptor knockout mice show a delay in age-related changes of body composition and bone characteristics. J Gerontol A Biol Sci Med Sci. 2006;61:562-567.
8. Egecioglu E, Andersson IJ, Bollano E, et al. Growth hormone receptor deficiency in mice results in reduced systolic blood pressure and plasma renin, increased aortic eNOS expression, and altered cardiovascular structure and function. Am J Physiol Endocrinol Metab. 2007;292:E1418-E1425.
9. Bellush LL, Doublier S, Holland AN, Striker LJ, Striker GE, Kopchick JJ. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology. 2000;141:163-168.
10. Wang M, Miller RA. Fibroblasts from long-lived mutant mice exhibit increased autophagy and lower TOR activity after nutrient deprivation or oxidative stress. Aging Cell. 2012;11:668-674.
11. Salmon AB,MurakamiS, Bartke A, Kopchick J, Yasumura K, Miller RA. Fibroblast cell lines from young adult mice of long-lived mutant strains are resistant to multiple forms of stress. Am J Physiol Endocrinol Metab. 2005;289:E23-E29.
12. Berryman DE, List EO, Kohn DT, Coschigano KT, Seeley RJ, Kopchick JJ. Effect of growth hormone on susceptibility to diet-induced obesity. Endocrinology. 2006;147:2801-2808.
13. Ikeno Y, Hubbard GB, Lee S, et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/ binding protein knockout mice. J GerontolABiol SciMedSci. 2009; 64:522-529.
14. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011;3:70ra13.
15. Steuerman R, Shevah O, Laron Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol. 2011;164:485-489.
16. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res. 2007;17:54-57.
17. Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods. 1998;14:381-392.
18. Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA. 1988;85:5166-5170.
19. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of thegrowth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;284: 19937-19944.
20. MavalliMD,DiGirolamo DJ, Fan Y, et al. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J Clin Invest. 2010;120:4007-4020.
21. Vijayakumar A,WuY, Sun H, et al. Targeted loss ofGHRsignaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes. 2012;61:94-103.
22. WuY, Liu C, Sun H, et al. Growth hormone receptor regulatesß cellhyperplasia and glucose-stimulated insulin secretion in obese mice. J Clin Invest. 2011;121:2422-2426.
23. Lu C, Kumar PA, Sun J, et al. Targeted deletion of growth hormone (GH) receptor in macrophage reveals novel osteopontin-mediatedeffects of GH on glucose homeostasis and insulin sensitivity in dietinduced obesity. J Biol Chem. 2013;288:15725-15735.
24. List EO, Berryman DE, Funk K, et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol. 2013;27:524-535.
25. Postic C, Shiota M, Niswender KD, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic ß cellspecific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274:305-315.
26. LaksoM,Pichel JG, Gorman JR, et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad SciUSA. 1996;93:5860-5865.
27. Masternak MM, Al-Regaiey KA, Bonkowski MS, Panici JA, BartkeA. Effect of every other day feeding diet on gene expression in normal and in long-lived Ames dwarf mice. Exp Gerontol. 2005;40:491-497.
28. Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, et al. Caloric restriction results in decreased expression of peroxisome proliferator- activated receptor superfamily in muscle of normal and long-lived growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci. 2005;60:1238-1245.
29. Sun LY, D'Ercole AJ. Insulin-like growth factor-I stimulates histone H3 and H4 acetylation in the brain in vivo. Endocrinology. 2006; 147:5480-5490.
30. List EO, Palmer AJ, Berryman DE, Bower B, Kelder B, Kopchick JJ. Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes. Diabetologia. 2009;52: 1647-1655.
31. Salmon DM, Flatt JP. Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. Int J Obes. 1985;9:443-449.
32. Palmer AJ, Chung MY, List EO, et al. Age-related changes in body composition of bovine growth hormone transgenic mice. Endocrinology. 2009;150:1353-1360.
33. Berryman DE, List EO, Coschigano KT, Behar K, Kim JK, KopchickJJ. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res. 2004;14:309-318.
34. Lubbers ER, List EO, Jara A, et al. Adiponectin in mice with altered GH action: links to insulin sensitivity and longevity? J Endocrinol.2013;216:363- 374.
35. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatalgrowth. Dev Biol. 2001;229:141-162.
36. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;96:7324-7329.
37. Sjögren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad SciUSA. 1999;96:7088-7092.
38. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110: 771-781.
39. Sjögren K, Sheng M, Movérare S, et al. Effects of liver-derived insulin- like growth factor I on bone metabolism in mice. J Bone Miner Res. 2002;17:1977-1987.
40. Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci USA. 2008;105:19378-19383.
41. Sos BC, Harris C, Nordstrom SM, et al. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest. 2011;121:1412-1423.
42. Shi SY, Martin RG, Duncan RE, et al. Hepatocyte-specific deletionof Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem. 2012;287:10277-10288.
43. Engblom D, Kornfeld JW, Schwake L, et al. Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev. 2007;21:1157-1162.
44. Friedbichler K, Themanns M, MuellerKM,et al. Growth-hormoneinducedsignal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology. 2012;55:941-952.
45. Sjögren K, Jansson JO, Isaksson OG, Ohlsson C.Amodel for tissuespecific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I. Endocrine. 2002;19:249-256
46. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003;63:4384-4388.
47. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10:127-140.
48. Smith WJ,NamTJ, Underwood LE, BusbyWH,Celnicker A, ClemmonsDR. Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab. 1993;77:1294-1299.
49. Wheatcroft SB, KearneyMT,ShahAM,et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes. 2007;56:285-294.
50. Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab. 2010;11:11-22.
51. Dozmorov I, Galecki A, Chang Y, Krzesicki R, Vergara M, Miller RA. Gene expression profile of long-lived snell dwarf mice. J Gerontol A Biol Sci Med Sci. 2002;57:B99-B108.
52. Kawai M, Breggia AC, DeMambro VE, et al. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem. 2011; 286:14670-14680.
53. Das SK, Bhutia SK, Azab B, et al. MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Res. 2013;73: 844-854.
54. Foulstone EJ, Zeng L, Perks CM, Holly JM. Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology. 2013;154:1780-1793.
55. Guo C, Lu H, Gao W, et al. Insulin-like growth factor binding protein- 2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS One. 2013;8:e74973.
56. Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith D. Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes. 2003;52:2483-2489.
57. Nordstrom SM, Tran JL, Sos BC, Wagner KU, Weiss EJ. Disruption of JAK2 in adipocytes impairs lipolysis and improves fatty liver in mice with elevated GH. Mol Endocrinol. 2013;27:1333-1342.
58. Pinidiyapathirage MJ, Dassanayake AS, Rajindrajith S, et al. Nonalcoholic fatty liver disease in a rural, physically active, low income population in Sri Lanka. BMC Res Notes. 2011;4:513.
59. Zhang H, He SM, Sun J, et al. Prevalence and etiology of abnormal liver tests in an adult population in Jilin, China. Int J Med Sci. 2011;8:254-262.
60. Fernandes MT, Ferraro AA, de Azevedo RA, Fagundes Neto U. Metabolic differences between male and female adolescents with non-alcoholic fatty liver disease, as detected by ultrasound. Acta Paediatr. 2010;99:1218-1223.
61. Haentjens P, Massaad D, Reynaert H, et al. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. Acta Clin Belg. 2009;64:483-493.
62. Spruss A, Henkel J, Kanuri G, et al. Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. Mol Med. 2012;18:1346-1355.
63. Fernandez-Perez L, Guerra B, Diaz-Chico JC, Flores-Morales. A Estrogens regulate the hepatic effects of growth hormone, a hormonal interplay with multiple fates. Front Endocrinol (Lausanne). 2013;4:66.
64. Svensson J, Sjogren K, Faldt J, et al. Liver-derived IGF-I regulates mean life span in mice. PLoS One. 2011;6:e22640.
65. Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004;113:96-105.
66. Nam SY, Lobie PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev. 2000;1:73-86.
67. Blüher S, Kratzsch J, Kiess W. Insulin-like growth factor I, growth hormone and insulin in white adipose tissue. Best Pract Res Clin Endocrinol Metab. 2005;19:577-587.
68. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009; 30:152-177.
69. Berryman DE, Glad CA, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol. 2013;9:346-356.
70. Chikani V, Ho KK. Action of GH on skeletal muscle function: molecular and metabolic mechanisms. J Mol Endocrinol. 2014;52: R107-R123.
71. Schuenke MD, Kopchick JJ, Hikida RS, Kraemer WJ, Staron RS. Effects of growth hormone overexpression vs. growth hormone receptor gene disruption on mouse hindlimb muscle fiber type composition. Growth Horm IGF Res. 2008;18:479-486.
72. Vijeyta F. Effects of Growth Hormone on Circulating Resistin Levels in Mice. Athens, OH: Ohio University Masters Thesis; 2012:1-141.